Glaukos Corporation (GKOS)

NYSE: GKOS · IEX Real-Time Price · USD
51.38 -1.82 (-3.42%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap2.41B
Revenue (ttm)294.01M
Net Income (ttm)-38.37M
Shares Out46.89M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume482,345
Open53.01
Previous Close53.20
Day's Range50.68 - 53.53
52-Week Range39.35 - 99.00
Beta1.67
AnalystsHold
Price Target55.75 (+8.5%)
Earnings Daten/a

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is des...

IndustryHealth Care Equipment & Supplies
IPO DateJun 25, 2015
CEOThomas Burns
Employees653
Stock ExchangeNYSE
Ticker SymbolGKOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for Glaukos stock is "Hold." The 12-month stock price forecast is 55.75, which is an increase of 8.51% from the latest price.

Price Target
$55.75
(8.51% upside)
Analyst Consensus: Hold

News

Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial reductio...

1 week ago - Benzinga

Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 week ago - Business Wire

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 week ago - Business Wire

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 week ago - Business Wire

Glaukos Announces FDA 510(k) Clearance of iPRIME™

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 weeks ago - Business Wire

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

3 weeks ago - Zacks Investment Research

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 weeks ago - Business Wire

Glaukos Announces Retirement of William J. Link, Ph.D.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 month ago - Business Wire

Glaukos Announces Participation in Upcoming Investor Conferences

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual M...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

2 months ago - Zacks Investment Research

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 17.39% and 3.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Glaukos Corporation Announces Third Quarter 2021 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Why Glaukos Stock Is Soaring Today

CMS' final payment rates for 2022 spurred an analyst upgrade for Glaukos.

2 months ago - The Motley Fool

Why Are Glaukos Shares Rallying Today?

Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for 202...

2 months ago - Benzinga

Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractiv...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos

Glaukos Corp (NYSE:GKOS) has settled a patent infringement lawsuit with Ivantis Inc. The lawsuit was initiated by Glaukos in 2018 in the U.S. District Court for the Central District of California, South...

4 months ago - Benzinga

Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

4 months ago - Zacks Investment Research

Glaukos Files Pre-Market Application For Intraocular Pressure Device

Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System. Related Content:   William Blair Downgrades...

4 months ago - Benzinga

Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire